Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tarafenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 20/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 20/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarafenacin SCHEMBL2278272 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Tarafenacin SCHEMBL29352113 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Tarafenacin SCHEMBL3751324 | 0.99 | CHRM3 (0.98) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Tarafenacin SCHEMBL3751328 | 0.99 | CHRM3 (0.98) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL13812723 | 0.94 | CHRM3 (0.88) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006034 | 0.91 | CHRM1 (0.85) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006033 | 0.91 | CHRM1 (0.85) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006871 | 0.90 | CHRM2 (0.86) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006110 | 0.90 | CHRM2 (0.90) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006869 | 0.90 | CHRM2 (0.86) | CHRM2CHRM1CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871787-B2 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester | LABORATORIOS SALVAT, S.A. (ES) | 2014-10-28 | — | — | US | claimed |
| US-8492402-B2 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester | LABORATORIOS SALVAT, S.A. | 2013-07-23 | — | — | US | claimed |
| US-20110207769-A1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER | LABORATORIOS SALVAT, S.A. (ES) | 2011-08-25 | — | — | US | claimed |
| US-8871787-B2 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester | LABORATORIOS SALVAT, S.A. (ES) | 2014-10-28 | — | — | US | disclosed |
| US-8871787-B2 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester | LABORATORIOS SALVAT, S.A. (ES) | 2014-10-28 | — | — | US | disclosed |
| US-8871787-B2 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester | LABORATORIOS SALVAT, S.A. (ES) | 2014-10-28 | — | — | US | disclosed |
| US-8871787-B2 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester | LABORATORIOS SALVAT, S.A. (ES) | 2014-10-28 | — | — | US | disclosed |
| EP-2220082-B1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICIYCLO [2.2.2]OCT-3-YL ESTER | SALVAT LAB SA (ES) | 2014-06-25 | — | — | EP | disclosed |
| EP-2220082-B1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICIYCLO [2.2.2]OCT-3-YL ESTER | SALVAT LAB SA (ES) | 2014-06-25 | — | — | EP | disclosed |
| US-20140051721-A1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER | LABORATORIOS SALVAT, S.A. (ES) | 2014-02-20 | — | — | US | disclosed |
| US-20140051721-A1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER | LABORATORIOS SALVAT, S.A. (ES) | 2014-02-20 | — | — | US | disclosed |
| WO-2009068253-A3 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-YL ESTER | SALVAT LAB SA (ES) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009068253-A2 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-YL ESTER | LABORATORIOS SALVAT, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068253-A2 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-YL ESTER | LABORATORIOS SALVAT, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| EP-2065385-A1 | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester | Laboratorios SALVAT, S.A. (ES) | 2009-06-03 | — | — | EP | disclosed |
| EP-2049533-A2 | QUINUCLIDINE DERIVATIVES AS M3 ANTAGONISTS | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-04-22 | — | — | EP | disclosed |
| US-7452904-B2 | 1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-11-18 | — | — | US | disclosed |
| US-20080039493-A1 | Quinuclidine derivatives as M3 antagonists | CHIESI FARMACEUTICI S.P.A. | 2008-02-14 | — | — | US | disclosed |
| WO-2008012290-A2 | QUINUCLIDINE DERIVATIVES AS M3 ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-01-31 | — | — | WO | disclosed |
| US-20050043349-A1 | 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists | LABORATORIOS S.A.L.V.A.T. (ES) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051721-A1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER | SLC10A2, HDAC6, SLCO1B3 | CHRM3 1747/4885CHRM2 1646/4885CHRM1 2360/4885 |
| US-20080039493-A1 | Quinuclidine derivatives as M3 antagonists | CHRM4, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 4/4885CHRM1 3/4885 |
| US-20050043349-A1 | 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885CHRM1 3/4885 |
| US-20110207769-A1 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER | SLC10A2, HDAC6, SLCO1B3 | CHRM3 1747/4885CHRM2 1646/4885CHRM1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.